Matrix Metalloproteinase 14 in Corneal Neovascularization
International Journal of Molecular Sciences · 20.02.2026 · 27 (4) · 2027
DOI: 10.3390/ijms27042027 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 20.02.2026. Verfasst von Kaley Qin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, College of Medicine, University of Illinois Chicago, Chicago, IL 606…. Hauptthemen laut MEDLINE: Corneal Neovascularization, Matrix Metalloproteinase 14. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 220 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, NIH HHS, VA.
Abstract (Originalsprache)
Corneal neovascularization (CoNV) disrupts the natural avascularity of the cornea, leading to loss of transparency and visual impairment. Among matrix metalloproteinases (MMP), MMP-14, a membrane-bound MMP, plays a central role in CoNV through matrix remodeling, activation of pro-MMP-2, modulation of growth factors-induced signaling, and regulation of vascular endothelial cell behavior. Under pathogenic conditions, MMP-14 promotes angiogenesis by degrading stromal collagen, enhancing vascular endothelial growth factor (VEGF) signaling, and stimulating vascular endothelial cell migration. However, MMP-14 can also exert anti-angiogenic effects by generating endostatin-like fragments such as neostatin-14. MMP-14 also participates in corneal wound healing and lymphangiogenesis, making it a promising therapeutic target for CoNV. Standard therapies for CoNV, such as corticosteroids, immunosuppressants, and anti-VEGF agents, remain partially effective. Novel strategies targeting MMP-14, including small-molecule inhibitors, selective use of TIMP-2, and recombinant antibodies, are being explored. A deeper understanding of how membrane-bound MMP-14 is regulated and functions in different contexts may allow better modulation of angiogenesis, ultimately preserving corneal clarity and visual function after injury or inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, College of Medicine, University of Illinois Chicago, Chicago, IL 60612, USA.
- Department of Pharmaceutical Sciences, College of Pharmacy and Biophysics Core, the Research Resource Center, University of Illinois at Chicago, Chicago, IL 60607, USA.
- Jesse Brown Veterans Affairs Medical Center, Chicago, IL 60612, USA.
ORCID-Profile: Kaley Qin, Nicholas W Setter, Hyun Lee, Jin-Hong Chang, Kyuyeon Han
Förderung
- NEI NIH HHS
- NIH HHS
- VA
- National Institutes of Health
- Department of Veterans Affairs
Zitieren
APA
Qin, K., Setter, N. W., Yu, L., Vasi, Z., Wu, W., Hwang, Y., Lee, H., Chang, J. H., Rosenblatt, M. I., Han, K., & Azar, D. T. (2026). Matrix Metalloproteinase 14 in Corneal Neovascularization. International Journal of Molecular Sciences, 27(4), 2027. https://doi.org/10.3390/ijms27042027
Vancouver
Qin K, Setter NW, Yu L, Vasi Z, Wu W, Hwang Y, et al. Matrix Metalloproteinase 14 in Corneal Neovascularization. International Journal of Molecular Sciences. 2026;27(4):2027. doi:10.3390/ijms27042027
BibTeX
@article{Qin2026,
author = {Qin, Kaley and Setter, Nicholas W and Yu, Lily and Vasi, Zahra and Wu, Weiyu and Hwang, Yunjeong and Lee, Hyun and Chang, Jin-Hong and Rosenblatt, Mark I and Han, Kyuyeon and Azar, Dimitri T},
title = {Matrix Metalloproteinase 14 in Corneal Neovascularization},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {4},
pages = {2027},
doi = {10.3390/ijms27042027}
}
EUVIMED